×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
200
500
All
Acquired Podcast: The Scientific Journey Behind Ozempic
FDA Issues Alert on Compounded Semaglutide Dosing Errors
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk’s CagriSema Falls Short of Weight Loss Expectations in REDEFINE 2 Trial
Retatrutide’s First Phase 3 Diabetes Results Draw Attention for More Than Strong Numbers
Sustained Weight Loss and Cardiovascular Risk Reduction with Wegovy
Articles
Professor Juleen R. Zierath: Three Decades of Showing How Exercise Changes Metabolism
A More Human View of Glucose: How Hourly Visualizations Reduce Anxiety and Reveal Real Patterns
Wegovy Will Not Go OTC: What the Sources Actually Say
Bridging Data and Healthcare in the Nordics
How Well Do My CGM and BGM Readings Match?
Epigenetic Clues to Heart Risk in Type 2 Diabetes
Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
Why mRNAs Are a Good Option for Vaccines
Why I Took Medical Courses to Strengthen My Data Skills
New Research Reveals the Hidden Complexity of Insulin Resistance
What the 2025 Diabetes Care Updates Mean for You
How an Hour-by-Hour View Transforms Time in Range Insights
Successfully Completed: Diabetes – A Global Challenge
Join the 5K@ADA Virtual Challenge to Promote Diabetes Awareness and Healthy Living
How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
FDA Issues Alert on Compounded Semaglutide Dosing Errors
Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living
Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea
News
March 2026
Novo Nordisk Reports Promising Phase 2 Data for UBT251 in Type 2 Diabetes
Novo Nordisk Expands DTC Push With New Wegovy Subscription Program
FDA Approves Awiqli as First Once-Weekly Basal Insulin for Type 2 Diabetes
Retatrutide’s First Phase 3 Diabetes Results Draw Attention for More Than Strong Numbers
FDA Approves Wegovy HD, Adding a Higher-Dose Semaglutide Option for Obesity
Zealand Pharma Reports Phase 2 Results for Petrelintide
February 2026
REDEFINE-4 Results: What They Mean for Patients
Novo Nordisk Renames Oral Semaglutide as Ozempic Pill Ahead of U.S. Launch
January 2026
Wegovy Oral Pill Launches in United States
Top Subjects
Type 2 Diabetes
Novo Nordisk
Obesity Treatment
GLP-1
Wegovy
Semaglutide
Eli Lilly
Tirzepatide
Ozempic
Zepbound
FDA Approval
Diabetes
Obesity
Diabetes Management
Continuous Glucose Monitoring
Mounjaro
Clinical Trials
Metabolic Health
Obesity Care
Orforglipron
Dexcom
CGM
Weight Loss
Oral Semaglutide
FDA
Rybelsus
Diabetes Treatment
Once-Weekly Insulin
Dexcom G7
Liraglutide
Contact Us
How many eyes does a typical person have?
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
